Published Date: 9-Mar-2021
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Inhaled Nitric Oxide Market, published by KBV research, The Global Inhaled Nitric Oxide Market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period. Inhaled nitric oxide is a therapeutic therapy with broad capabilities for pediatric clinical usage. The usage of nitric oxide is secure in some intensive care surroundings under observation. Nitric Oxide serves various benefits on ventilation & gas exchange and significantly enhances children with hypoxia.
The Neonatal Respiratory Treatment market dominated the Global Inhaled Nitric Oxide Market by Application in 2019. Infant respiratory treatment is among the major factor which is anticipated to increase the growth rate of inhaled nitric oxide during the forecast period. This growth is attributed to the increasing prevalence of diseases in infants like neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension. The Chronic Obstructive Pulmonary Disease (COPD) market is expected to witness a CAGR of 7.6% during (2020 - 2026).
The North America market dominated the Global Inhaled Nitric Oxide Market by Region in 2019. Asia-Pacific would grow significantly due to the largest number of live birth per 1000 people and a surge in occurrences of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure due to the persistent pulmonary hypertension of the newborn (PPHN). Moreover, the regional market is highly competitive in nature which is due to the presence of local providers of nitric oxide therapy systems. The Europe market would showcase a CAGR of 7.4% during (2020 - 2026).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.
Unique Offerings from KBV Research